LifeCell International to bring NxG stem cells technology to India (Chennai, May 20, 2009)
Exclusive tie-up with Harvest Technologies to launch Bone Marrow Aspirate Concentrate system in India
An update on the ongoing clinical trials for Critical Limb Ischemia in India Chennai
LifeCell International India’s first & the largest stem cell banking service provider, which has also pioneered in stem cell research and technology, today announced its association with Harvest Technologies, a world leader in developing technologies that accelerate natural healing, to bring-in a next generation technology Bone Marrow Aspirate Concentrate (BMAC) system in India. BMAC is a USFDA and CE approved biological technology that accelerates the body’s natural healing capacity, thereby improving surgical outcomes.
Existing methods to produce a stem cell concentrate therapy are time consuming, labour intensive, and require complex logistical considerations. The BMAC System helps in safe and rapid preparation of cell concentrate from bone marrow. The process takes only about 15 minutes and can be conducted in the point of care setting.
The system is currently being used clinically in many developed countries like US and Europe for various medical disciplines. These applications range from fractures, non-unions, osteonecrosis, cartilage repair applications and critical limb ischemia (CLI). The system will soon be applied for cardio vascular regeneration.
LifeCell has implemented this technology for an ongoing Indian CLI study which is being led by Dr. K. S. Vijayragavan at Department of Vascular Surgery, SRMC
. As per the data available on the interim study conduted on 30 patients after a 12 week followup major amputations were seen only in 4 patients and 6 of them went for minor amputation. The patients also reported significant reduction in their pain perception and considerable improvement in quality of life. The study also emphasised the fact that the BMAC process is safe and the Intra-arterial infusion does not cause any adverse reaction.
Talking on the association with Harvest Technologies, Mr. Mayur Abhaya, Executive Director, LifeCell International
says, “We are excited to partner with Harvest Technologies to bring-in international standards to India. LifeCell International is today India’s only comprehensive stem cells solutions provider as we offer a complete spectrum of services and with this association we intend to accelerate the availability of advanced stem cell therapy in India.
According to Scott Shea, Managing Director, Harvests Technologies GmbH
, “The Autologous regenerative cells from bone marrow offer profound potential for therapies. Harvest has conducted about 30,000 clinical procedures for various applications, the highest number of procedures in the world, using the BMAC System. Our novel technology now makes it possible to harvest the regenerative cells safely and rapidly in order to develop new therapies for heretofore incurable diseases”.
“We are delighted to be associated with LifeCell, an undisputed market leader in stem cell technology space and extend our services in India. LifeCell has a well established network with hospitals and clinical institutions across India and we would leverage their strength to rapidly deploy our service across the country and provide HOPE in addressing unmet medical challenges by offering cellular therapeutic ptions”.
Commenting on the interim report presented on the studies conducted for CLI in India using the BMAC technology, Mr. Mayur added
, “Through our clinical research, we have identified that the transplantation of autologous Bone Marrow Aspirate Concentrate (BMAC) into critically ischemic leg can increase blood flow and support in healing the wounds quickly. It also helps in reducing pain and avoiding leg amputation of otherwise incurable patients. This is also validated by the outcome of the CLI study which showed that 86.6% of patients could avoid amputation.”
About LifeCell International Pvt. Ltd:
LifeCell is India’s first & largest umbilical cord blood stem cell bank to bring the revolutionary concept of banking a baby’s umbilical cord blood stem to the country. LifeCell facilitates the cryogenic preservation of stem cells in technological collaboration with Cryo-Cell International Inc, USA - the world’s largest and oldest stem cell bank with more than 16 years of expertise in stem cell banking.
LifeCell in the past 4 years has positioned itself as leaders in the Industry and was recently accredited by AABB (American Association of Blood Banks) for adopting their international standards and today LifeCell is the “First & only AABB Accredited Stem Cell Bank in India” and recognized by DSIR, Govt. of India for R&D. Today LifeCell has over 20,000 members who have preserved their baby’s cord blood stem cells and has over 40 centers across India and abroad. The company will soon be launching another revolutionary service of Menstrual Blood Stem Cell Banking for every woman to preserve her stem cells and potentially secure her future from life-threatening diseases. With addition of this service LifeCell will become the first & only comprehensive stem cells solutions provider in the world to offer a complete spectrum of services in stem cells through multi-service banking, R&D, Clinical Trials and Stem Cell Therapy.
About Harvest® Technologies’ breakthrough BMAC™ (Bone Marrow Aspirate Concentrate) System:
Harvest Technologies has decades of cumulative experience designing, manufacturing and marketing devices for blood component separation, platelet sequestration, and bone marrow derived stem cell harvesting. Harvest® has received clearance in Europe to concentrate the cellular components from bone marrow via its breakthrough BMAC™ (Bone Marrow Aspirate Concentrate) System, currently being used in Europe to treat vascular, orthopedic and cardiovascular diseases. BMAC is the first and only product that makes possible the use of a clinically effective quantity of cellular compositions from a small aspirate of autologous bone marrow, which includes a large quantity of adult stem cells, derived from a patient at point-of care in just 15 minutes.
For media queries, please contact: